Nuclea Biotechnologies and Berkshire Medical Center agreed to work together to identify biomarkers that can guide the treatment of prostate and breast cancer. "I'm thrilled to be working with the Berkshire Medical Center and confident that this research will advance the use of biomarkers and yield more effective cancer treatments," Nuclea President and CEO Patrick Muraca said.

Related Summaries